Elekta secures €100 million EIB loan to advance cancer and neurological treatments
Swedish medtech company Elekta has obtained a loan of up to €100 million from the European Investment Bank to fund new cancer and neurological treatment research between 2026 and 2029.
Stockholm-based medical technology company Elekta has agreed to a loan of up to €100 million from the European Investment Bank (EIB). The financing is provided under the EIB Group's TechEU programme, which aims to strengthen European investment in strategic technologies and innovation while supporting EU goals in health research and competitiveness.
EIB Vice-President Karl Nehammer said Europe is home to world-leading medical-technology companies that need to keep investing and innovating, and that the new financing will support development of the next generation of cancer and neurological treatments.
Loan covers half of research programme
The EIB loan will finance up to half of a roughly €200 million research programme Elekta plans to run from 2026 to 2029, with most of the work based in Sweden and the Netherlands. In 2025, the EIB Group signed a total of €100 billion in new financing and advisory agreements across more than 870 projects related to climate action, digitalisation, security and defence, and social infrastructure.
Elekta was founded in 1972 by Lars and Laurent Leksell and is listed on Nasdaq Stockholm. The company develops precision radiation medicine used to treat cancers of the brain, breast, kidney, lung, pancreas and prostate, as well as certain neurological disorders. Its technology treats more than 2 million patients annually. Elekta employs around 4,000 people, maintains offices in over 40 countries, and sells its products in more than 120 markets.
Elekta Chief Financial Officer Klara Eiritz said growing demand for cancer care means healthcare providers need solutions that let them treat more patients without compromising quality or precision, and that the new financing gives the company added flexibility to pursue its long-term strategy.
The funding will support Elekta's work in radiotherapy, radiosurgery, brachytherapy and treatment-planning software, aiming to improve accuracy and efficiency in treating brain and body tumours, essential tremor and certain forms of epilepsy. The deal follows a recent EIB-backed €20 million financing agreement with Finnish digital pathology company Aiforia, signed in July.
